Literature DB >> 12674041

Anaphylactic reaction to cinoxacin: report of one case associated with inferior acute myocardial infarction.

O Quercia1, S Rafanelli, F Emiliani, G Francesco Stefanini.   

Abstract

Cinoxacin is an oral synthetic antibacterial agent, of the second generation quinolones group, with excellent efficacy in respiratory, intra-abdominal, pelvic, and skin and soft tissue infections. Overall, quinolones are well tolerated drugs, although phototoxicity and photoallergenicity is well demonstrated experimentally. In this report we show you a case of a man who presented a anaphylactic reaction associated with myocardial infarction, after taking a capsule of cinoxacin. We suppose that there is a direct participation of the heart in anaphylactic reactions, because acttivated mast-cells mediators can determine cardiovascular effects. Then performed double-blind placebo controlled challenge test with an alternative drug. We did not observe any adverse immediate or late adverse reaction to this drug.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12674041

Source DB:  PubMed          Journal:  Eur Ann Allergy Clin Immunol        ISSN: 1764-1489


  3 in total

1.  Drug-induced anaphylaxis : case/non-case study based on an italian pharmacovigilance database.

Authors:  Roberto Leone; Anita Conforti; Mauro Venegoni; Domenico Motola; Ugo Moretti; Ilaria Meneghelli; Alfredo Cocci; Giulia Sangiorgi Cellini; Stefania Scotto; Nicola Montanaro; Giampaolo Velo
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

2.  Acute ST-segment elevation myocardial infarction after amoxycillin-induced anaphylactic shock in a young adult with normal coronary arteries: a case report.

Authors:  Aristofanis Gikas; George Lazaros; Kalliopi Kontou-Fili
Journal:  BMC Cardiovasc Disord       Date:  2005-02-25       Impact factor: 2.298

3.  Ampicillin/sulbactam-induced Kounis syndrome with cardiogenic shock.

Authors:  Nicholas G Kounis; Ioanna Koniari
Journal:  Anatol J Cardiol       Date:  2017-02       Impact factor: 1.596

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.